Silence Therapeutics Final results for the year ended 31 December 2019 Final results for the year ended 31 December 2019 April 14, 2020 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of...

SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia January 15, 2019 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery,...